Trevi Therapeutics (TRVI) Depreciation & Amortization (CF) (2022 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Depreciation & Amortization (CF) of $34000.0 for Q1 2026, down 8.11% year-over-year from $37000.0 in Q1 2025, and up 9.68% quarter-over-quarter from $31000.0 in Q4 2025.
Powered by 
Analysis
Trevi Therapeutics (TRVI) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Trevi Therapeutics' Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $34000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 8.11% year-over-year to $34000.0; the TTM figure through Mar 2026 stood at $141000.0 (down 5.37% YoY), while the FY2025 annual figure was $144000.0, down 2.04% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $34000.0, up from $31000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $38000.0 in Q2 2024, with the low at $8000.0 in Q2 2022.
- The 5-year median for Depreciation & Amortization (CF) is $35000.0 (2023), against an average of $28882.4.
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) plunged 33.33% in 2022, then jumped 325.0% in 2023.
- Trevi Therapeutics' Depreciation & Amortization (CF) stood at $15000.0 in 2022, then soared by 133.33% to $35000.0 in 2023, then grew by 8.57% to $38000.0 in 2024, then slipped by 18.42% to $31000.0 in 2025, then increased by 9.68% to $34000.0 in 2026.
- Business Quant data shows TRVI's Depreciation & Amortization (CF) at $34000.0 in Q1 2026, $31000.0 in Q4 2025, and $38000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Trevi Therapeutics | 2.71 Bn | 2.71 Bn | - | 34,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 34,000.00 |
| Mar 31, 2026 | 34,000.00 |
| Dec 31, 2025 | 31,000.00 |
| Sep 30, 2025 | 38,000.00 |
| Jun 30, 2025 | 38,000.00 |
| Mar 31, 2025 | 37,000.00 |
| Dec 31, 2024 | 38,000.00 |
| Sep 30, 2024 | 36,000.00 |
| Jun 30, 2024 | 38,000.00 |
| Mar 31, 2024 | 35,000.00 |
| Dec 31, 2023 | 35,000.00 |
| Sep 30, 2023 | 35,000.00 |
| Jun 30, 2023 | 34,000.00 |
| Mar 31, 2023 | 19,000.00 |
| Dec 31, 2022 | 15,000.00 |
| Sep 30, 2022 | 9,000.00 |
| Jun 30, 2022 | 8,000.00 |
| Mar 31, 2022 | 11,000.00 |